Issue 5

Message From Our Chairman
My sincere thanks to all of our customers and research colleagues whose podium and poster presentations resulted in the most exciting of the 35 RSNA’s it has been my privilege to attend.  Also further validating PEM's clinical utility are recently published studies comparing PEM and MRI in both the journal Radiology and the European Journal of Nuclear Medicine and Molecular Imaging with 2 more manuscripts scheduled to be published in Q1 2011.  All this has generated an overwhelmingly positive response from the breast imaging community, which has resulted in dramatic, double-digit  increase in Orders and Sales.  This will enable us to continue to reinvest in additional research aimed at accelerating reductions in dose, improvements in image quality and new clinical applications.

While we have many commercial and technological achievements to be proud of, the one over-riding consideration that transcends those internal goals is our commitment and ability to make a difference in the lives of your patients.  To that end, I invite you to listen to two patient testimonials.  The first patient was only able to get a correct diagnosis from PEM; the second could not tolerate a Breast MR exam and found PEM to be not only an alternative, but as our recently published NIH data show, a better and more specific alternative, less likely to prompt unnecessary biopsies.

2010 is wrapping up to be a banner year. 2011 looks to be even dramatically better as we launch our technology in new markets around the world and expand, by a factor of 4, our distribution presence in the United States. I sincerely wish all of our customers a happy holiday season and a healthy and prosperous 2011.

Sincerely,

Paul Mirabella
Chairman & CEO

Radiology ePub of Landmark Prospective Multicenter Trial
Results from the NIH-sponsored* study published online in Radiology on November, 12, 2010 show that Positron Emission Mammography (PEM) was significantly more precise at identifying benign and cancerous lesions. Two-thirds of the biopsies prompted by PEM showed cancer compared to half of those prompted by MRI. This represents a significant improvement in specificity and resulted in a 26% improvement in positive predictive value (PPV). Physicians and women with breast cancer will welcome the potential reduction in cost and patient trauma associated with unnecessary biopsies. 
*NIH Grant # 5R44CA103102

Webinar of RSNA 2010 PEM Presentation by Dr. Wendie Berg
In case you missed Dr. Berg's presentations on PEM at RSNA 2010, we have recorded a 30-minute webinar version entitled: "Clinical Applications of Positron Emission Mammography" which is available on our website.

Radiology Paper Consensus Meeting

RSNA 2010 Naviscan Press Conference
Hear presentations from Dr. Wendie Berg, Dr. Mark Gittleman and Paul Mirabella at the RSNA 2010 Naviscan press conference featuring results from the NIH trial.

Patient Testimonials
Hear two unique personal perspectives from two patients whose lives were changed after having a PEM scan.  The first could not tolerate MRI due to severe claustrophobia and could only obtain successful diagnosis through PEM and PEM-guided biopsy. The second patient was only able to obtain the correct diagnosis thanks to PEM.

Featured Case Using 5.3 mCi of FDG
Many thanks to Dr. Kathy Schilling of Boca Raton Regional Hospital for sharing a compelling case of a patient who was imaged using half the usual dose of FDG resulting in 50% less radiation dose to the patient.   This patient who had a non-diagnostic breast MRI due to cystic breast disease was found on PEM and PEM-guided biopsy to have atypical lobular hyperplasia.  If you have a case you would like considered for our Featured Case series, please  This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Peer-Reviewed Publications and Upcoming Presentations

To subscribe to our Quarterly eNewsletter, please click here.